Skip to main content
Shop Plans Learn more about our coverage options including health, Medicare, dental and vision options for you, your family or your employees. Get Started Individual & Family Medicare Employer Vision Dental International Travel Find Care FAQ Blog Members Stay on top of your health care with helpful member resources. Members Home Medicare Health Dental Vision Find Care Member Knowledge Center Member Forms Medicare Forms Library Make a Payment Federal Employees Student Blue Healthy Blue Providers Access tools, policies and the latest information to help you care for our members. Providers Home Network Participation Networks & Programs Claims, Appeals & Inquiries Prior Authorization Services & CPT codes Prescription Drug Search Policies, Guidelines & Codes Provider News Provider FAQ Contact Us Employers Learn about our coverage options for small and large employers, and access tools and resources for your group. Employers Home Shop Employer Plans Employer Portal Support Member Forms & Resources Find Care Blog Agents Access the tools you need: rate quotes, applications, forms, the latest industry news, marketing materials and more. Agents Home Agent Services Check Eligibility Find Care Member Forms & Resources Medicare Forms Library
Contact Us
Log In
I am ... Please select A member A provider An employer An agent
Log in to Agent Services
Log in to Employer Services Register for Employer Services I'm registered but need portal access
Username Forgot username? Continue to Log In Register for Blue Connect Need help? Learn how to log in.
Log in to Blue e Register for Blue e Log in to Dental Blue
Back
Notification of Drug Policy Revisions Effective October 1, 2022 (Posted August 4, 2022) August 04, 2022
 Policy NameRevised Criteria
Botulinum Toxin Injection Adjusted duration of approval in initial and continuation sections to 48 weeks, and initial duration of approval for migraine to 24 weeks. Policy notification given 8/4/2022 for effective date 10/1/2022.
Immunoglobulin Therapy Added requirement of trial and failure of an IVIG product prior to use of a SCIG product unless other criteria are met. Added requirement of trial and failure of two preferred IVIG products prior to use of non-preferred IVIG products unless other criteria are met. Added requirement of trial and failure of Hizentra and Xembify prior to use of non-preferred SCIG products (Cutaquig, Cuvitru), and trial and failure of one preferred IVIG product prior to use of HyQvia unless other criteria are met. Added continuation criteria. Policy notification given 8/4/2022 for effective date 10/1/2022.
Injectable and Healthcare Administered Oncology Drugs Removed Herceptin Hylecta and Rituxan Hycela from policy and added to a separate individual policy (Preferred Injectable Oncology Program). Policy notification given 8/4/2022 for effective date 10/1/2022.
Patisiran (Onpattro) “Notification”Patisiran (Onpattro) Added requirement within initial and continuation sections that Onpattro will not be used in combination with Amvuttra or Tegsedi. Policy notification given 8/4/2022 for effective date 10/1/2022.
Preferred Injectable Oncology Program Added Herceptin Hylecta to policy as a non-preferred product with same criteria as Herceptin. Added Rituxan Hycela to policy as a non-preferred product with same criteria as Rituxan. Policy notification given 8/4/2022 for effective date 10/1/2022.